Uncomplicated UTI Management (IDSA 2011)
Uncomplicated UTI Management (IDSA 2011): Suspected UTI → Complicated UTI Risk Factors? → Complicated UTI.
Interactive Decision Tree
Algorithm Steps
- ▶Start
Suspected UTI
Dysuria, frequency, urgency in adult female
- ◆Decision
Complicated UTI Risk Factors?
Requires different management
- Male sex
- Pregnancy
- Diabetes
- Immunosuppression
- Urinary tract abnormality
- Recent instrumentation
- Symptoms >7 days
- Recent antibiotic use
- ⚠Warning
Complicated UTI
Obtain culture, broader spectrum therapy
- Urine culture before treatment
- Fluoroquinolone or beta-lactam
- 7-14 day course
- Consider imaging if not improving
- ID/urology consult if recurrent
- ◆Decision
Pyelonephritis Symptoms?
Upper tract involvement
- Fever >38°C
- Flank pain or CVA tenderness
- Nausea/vomiting
- Systemic symptoms
- ●Action
Acute Pyelonephritis
Culture required, consider admission
- Urine culture mandatory
- Outpatient: fluoroquinolone 7 days or TMP-SMX 14 days
- Admit if: unable to tolerate PO, pregnant, septic, obstruction suspected
- Consider CT if not improving 48-72h
- ●Action
Uncomplicated Cystitis
Healthy non-pregnant female
- Empiric treatment appropriate
- Culture not required if classic symptoms
- Urinalysis supportive but not required
- High probability if dysuria + frequency without vaginal symptoms
- ●Action
First-Line Antibiotics
IDSA recommended agents
- Nitrofurantoin 100mg BID x 5 days (avoid if CrCl <30)
- TMP-SMX 160/800mg BID x 3 days (if local resistance <20%)
- Fosfomycin 3g single dose (less effective)
- Avoid fluoroquinolones (FDA black box warning)
- ●Action
Alternative Antibiotics
If allergies or resistance concerns
- Beta-lactams: amoxicillin-clavulanate, cefpodoxime, cefdinir
- Less effective than first-line options
- Reserve fluoroquinolones for no other option
- 7 days if using beta-lactam
- ●Action
Symptomatic Relief
Adjunctive measures
- Phenazopyridine 200mg TID x 2 days (urine turns orange)
- Hydration encouraged
- Symptoms should improve 24-48h
- Complete course even if improved
- ◆Decision
Symptoms Resolved?
Assess response
- ✓Outcome
Resolved
No further action needed, return PRN
- ●Action
Persistent Symptoms
Culture-directed therapy
- Obtain urine culture
- Consider STI testing
- Treat based on susceptibilities
- Consider ultrasound if recurrent
- Urology referral if anatomic concern
- ●Action
Recurrent UTI (≥3/year)
Prevention strategies
- Post-coital prophylaxis: TMP-SMX or nitrofurantoin
- Continuous prophylaxis: low-dose nightly
- Self-start therapy for reliable patients
- Cranberry products (limited evidence)
- Vaginal estrogen in postmenopausal women
Guideline Source
IDSA Guidelines for Treatment of Acute Uncomplicated Cystitis and Pyelonephritis
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Applies only to uncomplicated UTI in non-pregnant women
- Local resistance patterns should guide antibiotic choice
- Does not address complicated UTI or pyelonephritis in detail
- Fluoroquinolone recommendations changed due to FDA warnings
- Asymptomatic bacteriuria treatment not addressed
Contraindicated Populations
Applicable Regions
AU: eTG recommends trimethoprim or nitrofurantoin first-line
UK: NICE recommends nitrofurantoin or trimethoprim
US: IDSA 2011 with updated FQ safety considerations
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Uncomplicated UTI Management (IDSA 2011)?
The Uncomplicated UTI Management (IDSA 2011) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on IDSA Guidelines for Treatment of Acute Uncomplicated Cystitis and Pyelonephritis.
What guideline is the Uncomplicated UTI Management (IDSA 2011) based on?
This algorithm is based on IDSA Guidelines for Treatment of Acute Uncomplicated Cystitis and Pyelonephritis (DOI: 10.1093/cid/ciq257).
What are the limitations of the Uncomplicated UTI Management (IDSA 2011)?
Known limitations include: Applies only to uncomplicated UTI in non-pregnant women; Local resistance patterns should guide antibiotic choice; Does not address complicated UTI or pyelonephritis in detail; Fluoroquinolone recommendations changed due to FDA warnings; Asymptomatic bacteriuria treatment not addressed. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Uncomplicated UTI Management (IDSA 2011) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free